The most promising finding was that the HLA-DQB1 6672G>C polymorphism was associated with clozapine-induced agranulocytosis, with an odds ratio of 16.9.31 A pharmacogenetic test based on this polymorphism has been marketed, but owing to low sensitivity (21.5%), it failed to be a commercial or clinical success.29, 32 In the first genome-wide association study, amino acid changes in HLA-DQB1 (126Q) and HLA-B (158T) were associated with clozapine-induced agranulocytosis with more modest odds ratios of 0.19 and 3.11, respectively.33 The gene discussed is HLA-B; the disease is Absence of circulating granulocytes.